Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management

MedXY Editorial Team•May 12, 2026•Clinical Updates

Clobetasol propionate ophthalmic suspension (CPN) 0.05% (BYQLOVI®) is the first super-potent (Class I) corticosteroid formulated for ophthalmic use.
Pooled Phase 3 data (CPN-301 and CPN-302) demonstrate that twice-daily (BID) dosing for 14 days achieves significantly higher rates of anterior chamber cell (ACC) clearance (58.2% vs. 17.3%) and pain resolution (88.5% vs. 45.8%) compared to placebo.
Unlike traditional high-potency steroids, CPN 0.05% shows no clinically meaningful increases in intraocular pressure (IOP) or deleterious effects on corneal endothelial cell density.
The rapid onset of action is evidenced by significant visual acuity improvements and pain relief as early as post-operative day (POD) 4.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Clobetasol propionate ophthalmic suspension (CPN) 0.05% (BYQLOVI®) is the first super-potent (Class I) corticosteroid formulated for ophthalmic use.
Pooled Phase 3 data (CPN-301 and CPN-302) demonstrate that twice-daily (BID) dosing for 14 days achieves significantly higher rates of anterior chamber cell (ACC) clearance (58.2% vs. 17.3%) and pain resolution (88.5% vs. 45.8%) compared to placebo.
Unlike traditional high-potency steroids, CPN 0.05% shows no clinically meaningful increases in intraocular pressure (IOP) or deleterious effects on corneal endothelial cell density.
The rapid onset of action is evidenced by significant visual acuity improvements and pain relief as early as post-operative day (POD) 4.